RxDoctor Payments Data

Leanne Young-Fritchie

Family · Boone, NCNPI 1346324159

Payments from drug & device makers

$560in general payments, 2019–2025

Across 29 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$284
  • AbbVie$154
  • AstraZeneca$54
  • Novo Nordisk$40
  • Pfizer$16
  • Genentech USA, Inc.$11

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC17$284
AbbVie7$154
AstraZeneca1$54
Novo Nordisk2$40
Pfizer1$16
Genentech USA, Inc.1$11

How this compares

$560 in reported general payments places this provider in the 55th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,301
Medicare patients
124
Services billed
452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide108$119,749
OzempicSemaglutide74$109,459
Tresiba Flextouch U-200Insulin Degludec44$71,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$67,934
JanuviaSitagliptin Phosphate54$62,193
EliquisApixaban52$59,401
JardianceEmpagliflozin27$22,939
Janumet XrSitagliptin Phos/Metformin Hcl14$17,741
RayaldeeCalcifediol12$15,829
LinzessLinaclotide15$13,947
Victoza 3-PakLiraglutide11$11,603
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$11,303
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,755
SymbicortBudesonide/Formoterol Fumarate29$10,007
Breo ElliptaFluticasone/Vilanterol17$9,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$284$119,749108 claims
Novo NordiskOzempic, Novolog$40$112,27885 claims
PfizerEliquis$16$59,40152 claims
AstraZenecaBreztri Aerosphere, Symbicort$54$20,76240 claims
AbbVieLinzess, Synthroid, Armour Thyroid$154$19,93379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,522 family providers in North Carolina.

Other family in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →